NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its acquisition of transplant diagnostics firm One Lambda for $925 million.

One Lambda, which had 2011 revenues of around $182 million, will become part of Thermo Fisher's Specialty Diagnostics Segment. The Canoga Park, Calif.-based firm develops tests that are used by transplant centers for tissue typing, mainly for determining compatibility between donors and recipients and for detecting the presence of antibodies that can result in transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.